GlobalNewsWire DUBLIN – May 24, 2017 – Medtronic plc (NYSE: MDT) today announced that the first patient has been enrolled in the IN.PACT(TM) AV Access Drug-Coated Balloon (DCB) study for use in patients with end-stage renal disease (ESRD). The U.S. Food and Drug Administration (FDA) approved the investigational device exemption […]
Peripheral/Endo
Avera Names Myles Greenberg MD CEO Of Alucent Medical
SIOUX FALLS, S.D.–(BUSINESS WIRE)–Myles D. Greenberg, MD, was named President and CEO of Alucent Medical, Inc., a new company licensed to develop a novel drug/device combination therapy for the treatment of peripheral vascular disease (PVD). The treatment, Natural Vascular Scaffolding (NVS)TM, has recently gained FDA approval to move forward with […]
Lombard Medical (LMT.L) Announces First Patient Enrolled And Treated In The ALTITUDE Registry For The Altura Stent Graft System
OXFORDSHIRE, U.K.–(BUSINESS WIRE)–Lombard Medical, Inc. (NASDAQ: EVAR), a developer, manufacturer and marketer of endovascular aortic aneurysm repair products, today announced that it has enrolled and treated the first patient in its global registry to evaluate its Altura® Endograft System. The ALTITUDE registry (ALTura Impact on the Treatment of Abdominal Aortic […]
Shockwave Medical Taps Former HeartWare (HTWR) Exec as New CEO
FREMONT, Calif.–(BUSINESS WIRE)–Shockwave Medical, a pioneer in the treatment of calcified cardiovascular disease, today announced the appointment of Doug Godshall as president and CEO. “We are excited to welcome an executive of Doug’s caliber and experience to the Shockwave team at this important time in the company’s development” Godshall was […]
Lombard Medical’s Endovascular Product Portfolio Presented at Scientific Sessions of the 39th Annual Charing Cross International Symposium
By Business Wire, May 04, 2017, 04:00:00 AM EDT OXFORDSHIRE, U.K.–(BUSINESS WIRE)– Lombard Medical, Inc. (NASDAQ:EVAR), a developer, manufacturer and marketer of endovascular aortic aneurysm repair products, today announced that its portfolio of endovascular stent graft systems, Altura® and Aorfix™, were featured in scientific presentations at the 39th annual Charing […]
Medeon Biodesign Announces Approval to Begin CE Clinical Study
TAIPEI, Taiwan, May 2, 2017 /PRNewswire/ — Medeon Biodesign, Inc., a Taiwan publically traded medical device company, is pleased to announce today that it has received approval by the Health and Disability Ethics Committees, Ministry of Health, New Zealand to commence the CE clinical trial for the XProTM Suture-Mediated Vascular […]
Intact Vascular Adds Howard Rosen to its Executive Management Team as VP Marketing and Business Development
WAYNE, Pa.–(BUSINESS WIRE)–Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced that Howard Rosen has joined its executive management team as Vice President of Marketing and Business Development. In this position, Mr. Rosen will lead the company’s efforts to prepare for commercialization of […]
Medtronic Drug-Coated Balloon (DCB) Demonstrates Consistent Results in Two New Analyses of Complex PAD Patients
Press Release DUBLIN and LONDON – April 25, 2017 – Medtronic plc (NYSE: MDT) today reinforced consistent results for its IN.PACT(TM) Admiral(TM) drug-coated balloon (DCB) with two new sub-analyses from the IN.PACT Global Study in patients with peripheral artery disease (PAD). The new data were reported at the annual 2017 […]
Endologix To Host An Investor Conference Call To Discuss Its Nellix Endovascular Aneurysm Sealing System Presentation At The Society Of Vascular Surgery Annual Meeting On June 3, 2017
IRVINE, Calif.–(BUSINESS WIRE)–Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that Dr. Jeffrey Carpenter’s submission “Refinement of the IFU for the Nellix® System for Endovascular Aneurysm Sealing Based Upon Outcomes From the EVAS FORWARD IDE Trial” has been accepted for a plenary […]
Five-Year Data from the Medtronic ENGAGE Registry Demonstrate Durable, Consistent, and Proven Outcomes in Real-World Setting
Source: Nasdaq Global Newswire DUBLIN and LONDON – April 26, 2017 – Medtronic plc (NYSE:MDT) today reported its Endurant® II abdominal aortic aneurysm (AAA) stent graft system continues to demonstrate long-term durability and consistent outcomes in a real-world setting. The five-year ENGAGE global registry data were presented for the first time […]



